Skip to main content

Newsroom

Press Releases

05/11/25 - 17:46

Price sensitive
Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised
Financial Data

31/10/25 - 10:12

Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration
Products Molecular

Press kit

Learn More

Video gallery

Learn More

Image gallery

Learn More